Episode Summary
In this episode of 340B Pulse, host Muhammad Atif speaks with Jason Bilyj, PharmD, ACE, Director of Pharmacy at Third Street Family Health Services, an FQHC in north central Ohio that opened its own in-house pharmacy in 2023. Jason walks through what claims-level data submission actually requires on the ground: reconciling four TPA platforms that don't report the same way, working inside a 45-day submission window he calls "really arbitrary," and absorbing manufacturer restrictions and pricing mismatches that cost Third Street roughly $200,000 a year.
He grounds that administrative burden in patient reality — about 30 percent of the patient population has transportation issues, half lack reliable internet access, and 12 percent are homeless — including the story of a patient buying insulin off Craigslist because her copay was too high, until Jason found her a year of free medication through a patient assistance program. He closes on the 340B rebate pilot's move to a per-claim vendor model in 2027, and on his unusual dual vantage point as a pharmacy director who also chairs the Finance Committee on Ontario, Ohio's City Council.
Show Notes
- The true definition of 340B claims-level data submission is not paperwork, it is a live workflow spanning four TPA platforms that do not agree with each other.
- Why most covered entities falsely assume a 45-day submission window is generous, when patient pickup timing alone can consume half of it.
- The critical difference between a TPA's auto-submit promise and a covered entity's actual legal responsibility for what gets submitted.
- Why most operators falsely assume manufacturer support portals function like customer service, when submitted tickets return with no ticket number and no record.
- The true cost of manufacturer restrictions and data submission failures, measured in nearly $200,000 a year at a single Ohio FQHC.
- Why most policy debate treats 340B transparency as a future decision, when Jason argues the ESP and TRUSO portals were never built to get covered entities the discount in the first place.
- The critical difference between a retail pharmacy's convenience model and an FQHC pharmacy built around transportation, connectivity, and homelessness in its own patient population.
- Why the 340B rebate pilot's move to a per-claim vendor model in 2027 trades pricing uncertainty for a new risk, fronting full drug cost with roughly ten days to get paid back.